Shijiazhuang Yiling Pharmaceutical (002603) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 was ¥4.60 billion, down 32.19% year-over-year due to high base and inventory in respiratory products.

• Net profit attributable to shareholders was ¥530 million, a 66.97% decrease year-over-year.

• Cash flow from operations fell 61.18% year-over-year to ¥264 million.

• R&D investment remained high at ¥411 million, 8.92% of revenue, leading the industry.

• Company remains a top innovator in Chinese patent medicine, with 14 proprietary products and strong market positions in cardiovascular and respiratory fields.

Financial highlights

• Operating income: ¥4.60 billion, down 32.19% year-over-year.

• Net profit: ¥530 million, down 66.97% year-over-year.

• Basic and diluted EPS: ¥0.3175, down 66.97% year-over-year.

• Gross margin: 53.37%, down 8.36 percentage points year-over-year.

• Cash and cash equivalents at period end: ¥1.22 billion, up 30.12% from year-end.

Outlook and guidance

• Company expects continued pressure on respiratory product demand due to high prior-year base and inventory.

• Focus remains on innovation, cost control, and efficiency to achieve annual profit targets.

• R&D pipeline includes multiple new drugs in late-stage clinical trials across cardiovascular, respiratory, and metabolic diseases.